«Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of mild to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic effects, serotonin-related side effects,[1] and adrenolytic effects (orthostatic hypotension and sexual dysfunction). As such it may be preferable to SSRIs in some patients. Mirtazapine is relatively safe if an overdose is taken.[2]»